SEATTLE, Sept. 23, 2022 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the upcoming Capital One Spatial Biology & Proteomics Summit taking place virtually on Wednesday, September 28, 2022.
Nautilus co-founder and CEO Sujal Patel is scheduled to participate in the following two executive panel discussions:
Interested parties may contact kristen.patrick@capitalone.com to register to attend the virtual event.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle and its research and development headquarters in the San Francisco Bay Area, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Media Contact
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
First Patients Enrolled in Pivotal Study Evaluating AIMIGo™ System for Synthesizing a 12-Lead ECG Ongoing…
Vancouver, British Columbia--(Newsfile Corp. - March 20, 2024) - Delivra Health Brands Inc. (TSXV: DHB)…
New Strategic Partnership Provides Funding to Support U.S. Growth Initiatives and Coronary Product Development, Opens…
Pioneering the Path of Sound Therapy with Biofield TuningBURLINGTON, VERMONT / ACCESSWIRE / March 20,…
ZURICH, SWITZERLAND / ACCESSWIRE / March 20, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or…
LOS ANGELES, CA / ACCESSWIRE / March 20, 2024 / The Skirball Cultural Center was…